The 3rd China Cardiovascular Devices Industry Investment CEO Conference was held in E-town on September 8. The conference aimed to build an effective platform for government, industry, investment and clinicians in cardiovascular, cerebral vascular and clinical fields. This is the first time that E-town has launched such a start-up event to seek quality projects in the field of cardio-cerebrovascular medical technology. E-town expects to attract more medical instrument enterprises through organizing such activities.

A leading industry in E-town, high-tech bio-medicine is gradually becoming a new brand of China’s intelligent manufacturing. In the first half of 2016, its output value reached 10 billion yuan.

JOINN Laboratories, Inc in E-town purchased Bayer’s R&D and manufacturing base in San Francisco and established JOINN innovative park in the US, starting a trend of Chinese bio-medical enterprises purchasing transnational corporations’ global R&D bases abroad. Early last year, Youcare Pharmaceutical Group Co., LTD acquired Actavis pharmaceutical factory, the third largest generics firm in the world, the first purchase by a Chinese chemical pharmaceutical enterprise of an American pharmaceutical factory.

Through overseas acquisition, JOINN Laboratories, Inc and Youcare Pharmaceutical Group Co not only obtained plants and equipment that meet American GMP standards but also obtained advanced software systems and expert personnel, which advances Chinese pharmaceutical enterprises’ ability to meet international standards and upgrades their research and development capacity.

As an important region of Beijing’s bio-medical industry, E-town clusters more than 700 competitive bio-medical enterprises such as Bayer, Sanofi, GE Healthcare and Tongrentang Group, which provide medicine and medical instruments and service while conducting medical research. The output value of E-town’s biological medicine reached 42.9 billion yuan in 2015, more than half of Beijing’s as a whole.